Generium, a Russian pharmaceutical company, established a joint venture (SG Biotech) with Shire, an Irish corporation. New partners already control about 70% of the government procurement market of drugs for hemophilia, which exceeded 8 billion rubles in the last year.
According to the Unified State Register of Legal Entities, SG Biotech was registered as a Russian legal entity in the fall of 2016.
The information provided on the website of SG Biotech states that the new company is engaged in bringing medicines for hemophilia (a hereditary disorder causing the impairment of blood clotting) to the Russian market. The spokesman of Shire announced that SG Biotech “combines the medicines for hemophilia in the portfolios of Generium and Baxalta, a pharmaceuticals manufacturer acquired by Shire in mid 2016 for $32 billion.”
“The joint venture will benefit from the synergy of experience accumulated by the two companies that are the founders in this field of medicine,” emphasized the representative of Shire. “The association will improve access to innovative methods of treatment and raise standards of medical care for hemophiliacs in Russia,” added the representative of Generium.